Loss of orally administered drugs in GI tract  by Gavhane, Yogeshkumar Nanasaheb & Yadav, Adhikrao Vyankatrao
Saudi Pharmaceutical Journal (2012) 20, 331–344King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLELoss of orally administered drugs in GI tractYogeshkumar Nanasaheb Gavhane a,*, Adhikrao Vyankatrao Yadav ba Dept. of Pharmaceutics, Govt. College of Pharmacy, Karad (MS), India
b Gaurishankar Education Society’s Institute of Pharmaceutical Education and Research, Limb, Satara (MS), IndiaReceived 3 March 2012; accepted 30 March 2012
Available online 20 April 2012*
E
av
13
El
Pe
htKEYWORDS
Drug–drug interaction;
Efﬂux transporters;
Cytochrome P450;
P-glycoprotein;
Gut wall/mucosal enzymes;
CYP3A4Corresponding author. Tel.
-mail addresses: gavhaneyo
yadav03@rediffmail.com (A
19-0164 ª 2012 King Saud
sevier B.V. All rights reserve
er review under responsibilit
tp://dx.doi.org/10.1016/j.jsps
Production and h/fax: +9
gesh@red
.V. Yada
Universit
d.
y of King
.2012.03.0
osting by EAbstract The aim of this review is to provide a broad perspective on intestinal absorption and the
impact of intestinal ﬁrst-pass metabolism on both clearance and drug–drug interaction prediction
along with its historical perspectives. The review also considers abilities to bridge the gap between
the increasing amount of intestinal in vitro data and the importance of intestinal ﬁrst-pass metab-
olism in vivo. The signiﬁcance of efﬂux transporters on the intestinal absorption is also discussed.
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As most of the drugs are xenobiotics, they undergo metabo-
lism by detoxiﬁcation system of human body. It leads to termi-
nating the effectiveness of moiety as a drug. The most desirable
route of administration for therapeutic agents is oral; as it
avoids pain and risk of infection associated with parenteral
administration and thereby increases patient compliance.
However most of the orally administered drugs display low
systemic availability and diminished efﬁcacy. The reasons are
two fold viz. formulation related and those related with GI
physiology. Factors that limit the drug release into the gastro-1 02164 271196.
iffmail.com (Y.N. Gavhane),
v).
y. Production and hosting by
Saud University.
05
lsevierintestinal lumen can be overcome with proper drug formula-
tion but ﬁrst-pass metabolism is an unavoidable obstacle, to
achieve an optimal bioavailability. For some new drugs like
HIV protease inhibitor saquinavir and the immunosuppressant
tacrolimus, a mean oral bioavailability of <20% is accepted in
the absence of a better alternative. Worst is the case for lido-
caine, fentanyl opioids and insulin, which effectively preclude
oral drug therapy.
The ability to successfully predict the pharmacokinetic
properties plays a crucial role in the selection of candidate
drugs and signiﬁcantly reduces the number of potential failures
in drug development. Current drug candidates typically show a
very high afﬁnity for the target receptors; however, the draw-
back is that many new lead compounds represent large, lipo-
philic molecules with low solubility, dissolution and/or
permeability and consequently show poor absorption proper-
ties. In vitro–in vivo correlation prediction, application of in
silico methods for clearance and drug–drug interaction predic-
tions from hepatic cytochrome P450 data have been widely ac-
cepted by both pharmaceutical companies and academia, and
have to meet certain regulatory requirements.
However, the application of these approaches to extrahe-
patic tissues, including the intestine, has proved to be challeng-
ing and less deﬁnitive. Estimates of intestinal clearance are not
routinely incorporated into in vitro–in vivo strategies and this
332 Y.N. Gavhane, A.V. Yadavmay partially explain the clearance under-prediction trend of-
ten observed.
The aim of this review is to provide a broad perspective,
both from academia and industry, on intestinal absorption
and the impact of intestinal ﬁrst-pass metabolism on both
clearance and drug–drug interaction predictions. The review
also considers abilities to bridge the gap between the increasing
amount of intestinal in vitro data and the importance of intes-
tinal ﬁrst-pass metabolism in vivo. Overviews of the biophar-
maceutical and pharmacokinetic variables and their impact
on the prediction of drug absorption from either chemical
structure and/or in vitro data are presented, focusing in partic-
ular on the estimation and application of intestinal permeabil-
ity. The role of uptake and efﬂux transporters and their
interplay with the metabolic enzymes is becoming an increas-
ingly important issue for drug candidates. Recently, drug elim-
ination mechanisms (e.g., via metabolism, or coupled with
uptake/efﬂux transporters or renal clearance) have been sug-
gested as criteria to extend the Biopharmaceutical Classiﬁca-
tion System beyond the use of drug permeability/solubility
characteristics to the prediction of drug disposition. The signif-
icance of efﬂux transporters on the intestinal absorption is also
discussed.
1.1. Historical
Until 1997, pre-systemic elimination was fully credited to the
liver. Also the attempts to deﬁne drug metabolism processes
have been limited largely to various metabolic isoenzymes of
the liver. Benet et al. (1996) and Wacher et al. (1996), were
the ﬁrst to hypothesize that for many drugs poor bioavailabil-
ity could be due to the action of intestinal enzymes. They had
performed certain cellular, animal and human studies and ar-
rived at a conclusion that intestinal metabolic enzymes and ef-
ﬂux transporters working coordinately as a protective
mechanism could be the cause for the poor bioavailability of
certain drugs. Prior to that, this problem was addressed for a
very restricted number of compounds (Ilett et al., 1990; Tam,
1993; Krisha and Klotz, 1994) and no attempt was made for
their quantitative determination and extraction evaluation.
This traditional view of intestinal metabolism has been reex-
amined by Thummel et al., 1997; Hall et al., 1999; Lin et al.,
1999; Zhag et al., 1999 in light of ﬁnding that enzymes of
the CYP3A sub-family (considered as major Phase I drug
metabolizing enzymes in humans) are expressed at high levels
in the premature villous tip enterocytes of the small intestine
(Waziers et al., 1990; Watkins et al., 1987; Murray et al.,
1988; Peters and Kerners, 1989; Kolars et al., 1992, 1994;
Mckinnon et al., 1995).
Active secretion of the absorbed drug is now being recog-
nized as a signiﬁcant factor in oral drug bioavailability (Benet
et al., 1996; Wacher et al., 1995). Of these multidrug efﬂux
pumps; the MDR1 gene product p-glycoprotein (P-gp) is of
particular interest. It was ﬁrst recognized in tumor resistance
(Leveque and Jehl, 1995).
Also CYP3A and P-gp share remarkable number of sub-
strates as common among them. Dexamethasone, etoposide,
rapamycin, taxol, and vinca alkaloids are a few of them
(Wacher et al., 1995).
Since then, several workers had worked on different enzyme
systems of the GIT. It was found that the intestinal mono-amine oxidase primarily acts on most of the amine containing
drugs. Sumatriptan and phenylephrine are a few of them (War-
ner et al., 1945; Lacey et al., 1995; Kanfer et al., 1993). Ester-
ase and amidase activities are distributed widely in the human
body including gastrointestinal tract (Leiweber1987). Alcohol
dehydrogenase present in the liver as well as the intestine plays
a major role in the metabolism of alcohol. Peptidases present
in the intestinal and pancreatic secretions split amide linkages
and thereby inactivate protein/polypeptide drugs. Bacterial
microﬂora of the colon and the gut wall are Phase II metabo-
lizing enzymes which also play a major role in the deactivation
of drugs as studied by several workers. Thummel et al., 1996;
Carrier et al., 2001 worked to quantitatively measure the
extraction of drug by the intestinal system.
The present article reviews general principles and pharma-
cokinetic models to study drug metabolism by the enzymes
in the gastrointestinal tract. It also focuses on variable drug re-
sponses due to variable enzyme expression and drug–drug, and
drug–food interactions.
2. Anatomical considerations
Drug metabolizing enzymes in the liver and gut mucosa are
present to limit the systemic exposure of foreign molecules that
have been absorbed from the gastrointestinal tract. This is an
evolutionary development in herbivorous or omnivorous ani-
mals. Any foreign molecule that is absorbed from the G.I. lu-
men travels across G.I. mucosa, capillary beds of small and
large intestine, liver via portal circulation and is then trans-
ported to the rest of the body organs. Only exception to this
is the molecules absorbed into the lymphatic system or distal
rectum which effectively bypass the liver (Thummel et al.,
1996; Shargel et al., 2006) (see Fig. 1).
The most optimal site for drug absorption is across the villi
of the proximal small intestine. Columnar epithelia that form
the surface barrier to gastrointestinal lumen contain high
amounts of oxidative, conjugative and hydrolytic drug metab-
olizing enzymes. Foreign molecules, which gain access to the
intestinal capillary bed by diffusion or transport across the
luminal plasma membrane of the most mature enterocytes,
must pass through this intracellular enzymatic barrier. Thus,
if enzyme activities are sufﬁciently high, ﬁrst pass metabolism
at the mucosal epithelium can approach 100% extraction efﬁ-
ciency (Thummel et al., 1996; Bramhankar and Sunil, 2005)
(see Fig. 2).
The architecture of the gastrointestinal mucosa is exqui-
sitely designed for xenobiotic absorption after oral intake.
Drug absorption at this site can be described as a sequence
of thermodynamically driven events. Disintegration of dosage
form and dissolution of drug can be controlled by formula-
tion but can be affected by peristaltic movement, luminal
pH, and the release of bile salts and the presence of food.
For most of the drugs (excluding some sustained release for-
mulations) absorption occurs from duodenum and jejunum.
Studies with Caco-2 cell monolayer cultures (a human colo-
rectal cell line) suggest that transcellular absorption predom-
inates for most of the lipophilic drugs, whereas the polar,
hydrophilic compounds are taken up via paracellular mecha-
nism (Thummel et al., 1996; Artursson, 1990; Artursson and
Karlsson, 1991; Meunier et al., 1995; Collett et al., 1996;
Watkins, 1994).
Figure 1 Drug absorption process in the GI tract.
Figure 2 Architecture of the gastrointestinal mucosa.
Loss of orally administered drugs in GI tract 333The movement of drug into the villous epithelium, positions
it for intracellular enzyme-catalyzed metabolism. For many
peptide or peptide-based drugs, extracellular enzyme-catalyzed
degradation can also occur within the epithelial brush border
and unstirred water layer (Meunier et al., 1995).
Drug in the intracellular or intercellular space will continue
to diffuse across a concentration gradient into the interstitial
space found between the epithelium basement membrane and
capillary endothelium and subsequently diffuse across a ‘leaky’
endothelium for delivery into capillary blood. Mucosal capil-lary blood ﬂow drains into the superior and inferior mesenteric
veins, which converge to form the hepatic portal vein (Thum-
mel et al., 1996).3. GI enzymes for presystemic metabolism
GI enzymes, which contribute for presystemic metabolism of a
drug, are categorized as (Bramhankar and Sunil, 2005; Wat-
kins, 1997; Watkins, 1994) (see Fig. 3).
Figure 3 Role of GI enzymes in metabolism of xenobiotics.
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(2) Gut wall/mucosal enzymes
(3) Bacterial enzymes.3.1. Luminal enzymes
 Introduction: These are the enzymes present in the gut
ﬂuids and include enzymes from pancreatic and intesti-
nal secretions.
 Peptidases: Insulin, calcitonin, teragastrin, thyrotropin
releasing hormone, phenyl alanine, glycine are a few of
the peptidyl drugs. But the oral bioavailability of these
drugs is generally poor, since they are poorly absorbed
and easily degraded by proteolytic enzymes in the gas-
trointestinal tract (Shargel et al., 2006; Lee and
Yamamoto, 1990).
 Esterases: Ester type drugs and prodrugs are hydro-
lyzed by esterases present in the intestinal tract (Crau-
ste-Manciet et al. 1997) and mucosa (Odgers et al.,
1995; Guerrero et al., 2006). A few studies have paid
much attention to the metabolism of ester prodrug in
the intestinal tract and mucosa (Feng et al., 2006;
Augustijns et al., 1998).4. Gut wall/mucosal enzymes
4.1. Introduction
These enzymes are mainly present in the stomach, intestine and
colon. Alcohol dehydrogenase is an enzyme of stomach muco-
sa that inactivates ethanol. Intestinal mucosa contains both
Phase I and Phase II enzymes. The colonic mucosa also con-
tains both Phase I and Phase II enzymes. However the en-
zymes of the proximal small intestine are most active.
4.2. CYP450
4.2.1. The cytochrome P450 enzyme system
The CYP450 enzyme system is a key pathway for drug metab-
olism. Most of the lipophilic drugs must undergo biotransfor-mation to more hydrophilic compounds to be excreted from
the body. Drug biotransformation reactions consist of Phase
I (e.g., oxidation, reduction) or Phase II (e.g., conjugation)
reactions that occur primarily in the liver. The most common
Phase I reaction is oxidation, which involves the insertion of
an oxygen atom into the compound to form a polar hydroxyl
group. Of the enzymes involved in the Phase I reactions, the
CYP450 group is the most important38.
Cytochrome P-450 is a superfamily of hemoproteins which
can be divided into families, subfamilies and/or single enzymes.
The cytochrome P-450 enzymes act as a major catalyst for
drug oxidation. To unify the nomenclature, a given gene fam-
ily is deﬁned as having >40% amino acid sequence homology
and a subfamily as having >55% identical sequence homol-
ogy. Using this nomenclature, the cytochrome P450 enzymes
are designated by the letters CYP (representing cytochrome
P450), followed by an Arabic numeral denoting the family, a
letter representing the subfamily (when 2 or more exist) and
another Arabic numeral designating the individual gene within
the subfamily (e.g., CYP2D6) (see http://www.
nursinglink.com).
Yan and Caldwell, 2001 have presented the status and given
detailed descriptions of biotransformation, metabolic stability
assays, identiﬁcation of drug metabolizing P450 enzymes, pre-
diction of pharmacokinetic parameters from in vitro metabo-
lism data, structure elucidation of metabolites, CYP450
inhibition assays and CYP450 induction assays from a drug
discovery perspective regarding the hepatic as well as the intes-
tinal CYP450s (Yan and Caldwell, 2001).
Each enzyme of the CYP family is termed as an isoform (or
isoenzyme) since it is derived from a different gene. An impor-
tant subset of the cytochrome P450 family is the CYP3A4 iso-
enzyme, which accounts for nearly 60% of the total CYP450 in
the liver and approximately 70% in the intestine. CYP3A4,
which catalyzes the biotransformation of many drugs, is signif-
icantly expressed extrahepatically (Cheng-Chung et al., 2001).
Extensive metabolism by CYP3A4 in the gastrointestinal tract
contributes to the poor oral bioavailability of many drugs.
Many substrates, inhibitors and inducers of CYP3A4 have
been identiﬁed. By deﬁnition, a substrate is a drug that is
metabolized by an enzyme system. An inhibitor decreases the
activity of the enzyme and may decrease the metabolism of
substrates, generally leading to an increased drug effect. Induc-
ers, however, may increase the metabolism of substrates and
generally lead to a decreased drug effect.38
They are mainly microsomal and found attached to the cell
endoplasmic reticulum. Only minimal amounts of CYP3A,
2E1, 2D6, 1A2 and 2C are found in the esophagus, stomach
and colon (Thummel et al., 1996). In contrast cytochromes
identiﬁed in human intestine include CYP1A1 (Wacher et al.,
2001; Buchthal et al., 1995), CYP2, CYP2D6, CYP2E1 (trace
amounts), CYP3A4 (Waziers et al., 1990; Kolars et al., 1992,
1994; Mckinnon et al., 1995) and more recently CYP3A5 (Ko-
lars et al., 1994). By far the most important of these enzymes in
drug metabolism is CYP3A4. Immunohistochemical studies
have shown that the small intestinal concentrations of
CYP3A4 are approximately, 80–100% of the CYP3A4 concen-
tration in the liver, while CYP2C8–10 concentrations are only
5–10% and CYP2D6 concentrations are around 20% of their
respective liver levels (Waziers et al., 1990). In addition, micro-
somes prepared from human jejunal enterocytes have demon-
strated CYP3A4 protein concentrations and enzyme activities
Loss of orally administered drugs in GI tract 335equal to or greater than those found in hepatic microsomes. In
a study of 20 full-length human small intestines, Paine et al.,
1997 found microsomal CYP3A4 expression to be continuous
along the entire length of the small intestine, but variable from
one region to the other. A mean value of 31 (<2–91), 23 (<2–
98) and 17 (<2–60) pmol/mg protein was detected in the duo-
denum, distal jejunum and distal ileum respectively. Sequential
analysis of each section of six intestines showed that the peak
expression varied, but was generally highest within the ﬁrst 10
feet distal to the pyloric valve. In the same study, the distribu-
tion pattern for NADH dependent cytochrome P450 reductase
activity closely paralleled to that of CYP3A protein. In con-
trast mucosal microsomal cytochrome b5, protein content
and b5 reductase activity tend to increase slightly in a proximal
to distal direction (see Fig. 4).
CYP3A5, which is expressed in only 25–30% of human liv-
ers (Wrighton et al., 1989), appears to be more commonly ex-
pressed in human intestine. It was found in intestinal biopsy
samples of fourteen patients out of twenty, which is almost
70%. Most recently in 2001 Carrier et al., 2001 had used
Caco-2 cells and primary cultures of pig enterocytes as a model
for in vitro testing. They also found that CYP3A4 was most
abundantly expressed in differentiated enterocytic cells.
Although absolute CYP3A5 levels were not quantiﬁed in this
study, they have found it much lower than CYP3A4 when en-
zyme and mRNA levels were measured in the small intestine
from an organ donor. The intestine was treated with CYP3A
inducers dexamethasone and phenytoin (Kolars et al., 1994).
In another study, CYP3A5 mRNA was absent in the intestinal
sample but was found in six of eleven colon samples (Peters
and Kerners, 1989).
Most of the workers tried to compare CYP3A4 and
CYP3A5 activities. Intestinal CYP3A5 appears not to be
inducible (Wrighton et al., 1989; Wrighton et al., 1990; Schuetz
et al., 1995) while CYP3A4 is induced by dexamethasone
(Watkins, 1994) and rifampicin (Kolars et al., 1992). Although
they are having similar substrate speciﬁcities, they signiﬁcantly
differ in catalytic activities (Wrighton et al., 1989; Wrighton
et al., 1990; Schuetz et al., 1993; Aoyama et al., 1989; Gorski
et al., 1994) for example, CYP3A4 and CYP3A5 show almost
equal abilities to metabolize nifedipine, however CYP3A5 does
not appear to catalyze erythromycin N-demethylation (Wrigh-
ton et al., 1990; Aoyama et al., 1989). Similarly, CYP3A4 is
known to convert cyclosporine to three major metabolites
(AM1, AM9, and AM4N) while CYP3A5 metabolizes cyclo-Figure 4 Expression of CYP3A5 and Cyt b5 reductase in the
duodenum and ileum.sporine to only one (AM9) (Aoyama et al., 1989). While
CYP3A5 also demonstrates regioselective metabolism of
midazolam, preferentially hydroxylating 10- as compared to
40-position by CYP3A4. And hence midazolam metabolite ra-
tios have been suggested as a useful probe of in vivo CYP3A
expression (Gorski et al., 1994).
4.2.2. In-vivo CYP-3A-dependent metabolism
Clinical evidence of signiﬁcant Phase-I metabolism by the
small intestine was available as early as 1977, in studies by Ma-
hon et al., 1977 who instilled C-labeled ﬂurazepam into the
stomach of one patient and duodenum of two others. Thin
layer chromatographic analysis of portal venous blood demon-
strated the rapid appearance of signiﬁcant levels of ﬂurazepam
metabolites, consistent with metabolism by the small intestinal
mucosa. With the advent of time, contribution of intestinal en-
zymes to ﬁrst-pass drug metabolism has become the focus of a
great deal of research, as a large number of drugs were found
to be substrates for CYP3A. CYP3A not only reduce the oral
bioavailability of a compound but also acts as a major source
of inter-individual variability in blood levels. Variable consti-
tutive enzyme expression and drug–drug interactions in turn
contribute to variable drug response.4.2.2.1. Cyclosporine. Much of the work establishing intestinal
metabolism as a major determinant of oral drug bioavailability
has been conducted using the immunosuppressive agent cyclo-
sporine. In a demonstration of CYP3A mediated intestinal
metabolism, Kolars et al., 1991 instilled cyclosporine into the
small bowel of two patients during the anhepatic phase of liver
transplantation. Analysis of portal venous blood showed 25%
and 51% of cyclosporine metabolites. It suggests that the
extraction by intestine is more important than the liver in dem-
onstrating cyclosporine bioavailability. Clinical pharmacoki-
netic studies have also provided strong evidence for extensive
intestinal extraction of cyclosporine. In three separate studies
i.v. and oral cyclosporine were administered to subjects either
alone or together with the CYP3A4 inducer rifampin (Hebert
et al., 1992) or the CYP3A4 inhibitors, ketoconazole (Gomez
et al., 1995) and erythromycin (Gupta et al., 1988). The effect
of the coadministered drug on the hepatic and intestinal
metabolism of cyclosporine can be differentiated by treating
the observed cyclosporine oral bioavailability (Fmeas.) as the
product of the fraction absorbed intact from the intestinal lu-
men (Fabs) multiplied by the fraction reaching the portal
blood unmetabolized by the intestine (Fg) multiplied by the
fraction passing through the liver unmetabolized (Fhep). Fhep
is calculated by i.v. cyclosporine clearance divided by hepatic
blood ﬂow. It is assumed as unaffected by the coadministered
drug, and hence the equation becomes simple as Fabs · Fg
(Hebert et al., 1992; Gomez et al., 1995; Chi-Yuan et al.,
1995). A comparison of the effects of rifampin, ketoconazole,
and erythromycin on oral cyclosporine pharmacokinetics is
presented in Table 1.
In each case, the changes in Fmeas caused by coadministra-
tion of these drugs were not reﬂected by changes in hepatic
extraction (Fhep) but were almost identical to changes in
Fabs · Fg. The dosing regimen was such that no effect of
inducers/inhibitors was expected on cyclosporine absorption.
Thus the drug induced changes in cyclosporine oral bioavail-
ability arose predominantly from their effects on intestinal
Table 1 Comparison of effects of rifampin, ketoconazole, and
erythromycin on oral cyclosporine pharmacokinetics.
Substrate Fa (%) Fhep (%) Fabs · Fg (%)
Cyclosporine
Alone 27 (11) 77 (4) 33 (13)
+Rifampin 10 (3) 68 (8) 14 (5)
Cyclosporine
Alone 22 (5) 75 (7) 30 (8)
+Ketoconazole 56 (12) 86 (4) 65 (11)
Cyclosporine
Alone 36 (9) 73 (10) 49d
+Erythromycin 62 (17) 80 (4) 78d
Table 2 Quantitative metabolism of drugs in the liver and gut.
Fabs (%) ERG XG
Rifampin
100 0.65 1.31
86 0.59 1.40
77 0.54 1.49
65 0.46 1.68
Ketoconazole
100 0.71 0.49
86 0.66 0.36
77 0.62 0.25
65 0.55 Indeterminate
Erythromycin
100 0.51 0.44
86 0.43 0.23
77 0.37 Indeterminate
336 Y.N. Gavhane, A.V. Yadavcyclosporine metabolism (Fg) (Hebert et al., 1992; Gomez
et al., 1995; Chi-Yuan et al., 1995). Boundary-condition anal-
ysis from this data demonstrated that at least 65% of an oral
cyclosporine dose is absorbed, however this dose is more than
50% extracted by the intestine (Chi-Yuan et al., 1995). Fig. 5
presents mean estimates of Benet et al., 1996 for Fabs (86%),
Fg (41%) and Fhep (76%) leading to the Fmeas value of 27%
for cyclosporine formulation in healthy volunteers (see Fig. 5).
Chi-Yuan et al. (1995) showed that approximately two
thirds of cyclosporine metabolism occurs in the gut, with the
liver responsible for only one third of metabolism. He also per-
formed three drug interaction studies in which the pharmaco-
kinetics of i.v. and orally administered cyclosporine was
determined in blood, both before and after oral administration
of a second known drug that alters the metabolism of cyclo-
sporine. These studies of the effects of dosing rifampin (Hebert
et al., 1992) (an inducer of cyclosporine metabolism), erythro-
mycin (Gupta et al., 1989) and ketoconazole (Gomez et al.,
1995) (inhibitors of cyclosporine metabolism) had served as
the basis for the analysis to differentiate hepatic and gut
metabolisms and to estimate the extent of absorption of cyclo-
sporine. The results are shown in Table 2.
Angela Sansone-Parsons et al., 2007 analyzed the pharma-
cokinetic properties of the immuno-suppressants cyclosporine
and tacrolimus when either is coadministered with oral posa-
conazole. Their ﬁndings suggest that the dosage of cyclospor-Figure 5 Extraction of cyclosporine through the gut
(percentage).ine or tacrolimus should be reduced when posaconazole
therapy is started and that plasma levels of the immunosup-
pressant should be monitored during and at the discontinua-
tion of posaconazole therapy so that dosages are adjusted
accordingly.
4.2.2.2. Midazolam. Kolars et al. (1994) had administered
midazolam into the small bowel of two patients during the
anhepatic phase of liver transplantation intravenously. They
have compared the extent of metabolism and found approx.
12% metabolism for i.v. administration. It suggests that the
intestinal metabolism plays a role in systemic as well as in
pre systemic clearance. Thummel (1995) had conducted a series
of studies in humans indicating that midazolam undergoes
extensive intestinal ﬁrst-pass metabolism. In a study of i.v.
and oral midazolam pharmacokinetics in 20 healthy volun-
teers, indirect estimates of the intestinal and hepatic ﬁrst pass
extraction fractions were 44 ± 14% and 43 ± 0.4% respec-
tively (Thummel et al., 1996). Direct veriﬁcation of signiﬁcance
of the small intestine as a site of ﬁrst pass metabolite extraction
for midazolam was done in liver transplant patients (Paine
et al., 1996). The difference between hepatic portal venous
and arterial midazolam and 10-hydroxymidazolam AUCs had
given mean 1st pass intestinal extraction fraction of 43%.
Saquinavir was shown to increase the oral bioavailability of
midazolam from 0.40 to 0.90, predominantly by increasing the
intestinal availability (Palkama et al., 1999).
Toﬁsopam inhibits the pharmacokinetics of CYP3A4 sub-
strate midazolam by inducing CYP3A enzymes (Ma´ria et al.,
2008).
Grape fruit juice has increased the oral bioavailability of
midazolam from 0.24 to 0.35 with no signiﬁcant alteration in
AUC of intravenously administered midazolam (Kupferschi-
midt et al., 1995).
4.2.2.3. Other substrates. The metabolism of a number of drugs
that undergo signiﬁcant ﬁrst pass extraction has been studied
in vitro using mucosal homogenates, mucosal microsomes or
intact mucosal membranes isolated from human intestine.
CYP3A catalyzed biotransformations including ﬂurazepam
(Mahon et al., 1977), ethinyl estradiol (Rogers et al., 1987),
erythromycin (Watkins et al., 1987), a cyclosporine analog
Loss of orally administered drugs in GI tract 337SDZ IMM 125 (Vickers et al., 1995), tacrolimus (Lampen
et al., 1995) and saquinavir (Fitzsimmons and Collins, 1997)
when normalized for total nmol of P450, the intestinal micro-
somes proved metabolically superior, reﬂecting the greater
contribution of the CYP3A fraction to total P450 content
(Paine et al., 1997).
All of the above drugs have demonstrated a greater extent
of intestinal metabolism as compared to hepatic metabolism.
One exception to this general trend is the report of a much low-
er (1/30) rate of microsomal oxidation by intestinal micro-
somes in comparison to hepatic microsomes.
Based on these limited studies, the mean mucosal micro-
somal intrinsic clearance is likely to be within two to three fold
of the corresponding hepatic microsomal intrinsic clearance
for the most CYP3A substrates.
Day Y. Lee et al., 2007 had observed after oral administra-
tion of omeprazole to cirrhotic rats, the AUC difference (of
451% and 149%) was greater than that after intravenous
administration. It was possibly due to a decrease in intestinal
ﬁrst-pass effect of omeprazole in addition to a decrease in he-
patic metabolism in cirrhotic rats.
Van et al. studied the extrahepatic metabolism of sevoﬂu-
rane by measuring the ﬂuoride production in children receiving
sevoﬂurane solely during the anhepatic phase of orthotopic li-
ver transplantation. Out of two groups, in one group, isoﬂu-
rane was replaced by sevoﬂurane as soon as the liver was
removed from the patient and maintained until reperfusion
of the new liver. Plasma ﬂuoride concentrations were deter-
mined by ion-selective electrode. The ﬂuoride concentration in-
creased signiﬁcantly as soon as sevoﬂurane was introduced; it
remained stable in the group receiving isoﬂurane. The peak
ﬂuoride concentration was also signiﬁcantly higher in the ﬁrst
group (mean ± SD: 5.5 ± 0.8 lM (sevoﬂurane group) versus
1.4 ± 0.5 lM (isoﬂurane group) P< 0.05). These results dem-
onstrate the existence of an extrahepatic metabolism of sevo-
ﬂurane in children with end-stage liver disease (Van et al.,
2000) (see Table 3).
Poet et al. (2003) evaluated the role of intestinal metabolism
in the ﬁrst-pass elimination of CPF (chlorpyrifos) and DZN
(diazinon). Similarly esterase-mediated metabolic proﬁles were
demonstrated in isolated intestinal enterocytes. Compared on
a per nmol P450 basis, the Vmax for CPF in enterocytes was
2–3 times higher than in liver microsomes for the production
of CPF-oxon and TCP. These results suggest that intestinalTable 3 Predicted intestinal ﬁrst-pass extraction ratios for
selected CYP3A substrates.
Drug ER (%)
Midazolam 38.3
Nifedipine 35.6
Felodipine 8.6
Diltiazem (HCl) 2.5
S-verapamil (HCl) 9.4
Quinidine 57.5
Saquinavir 99.3
Indinavir 11.8
Carbamazepine 0.2
Tracrolimus 14.2
Cyclosporine 3.3
Terfenadine 5.0metabolism may impact the ﬁrst-pass metabolism of CPF
and DZN, especially following low-dose oral exposures (Poet
et al., 2003).
Most recently Hyun et al. (2006) observed that intestinal
ﬁrst-pass effect of Sildenaﬁl was approx. 71% of oral dose
in rats. Gracia et al. (2003) had done a PK study with intes-
tinal elimination of albendazole sulfoxide. He found a clear
and statistically signiﬁcant interaction with verapamil with
43% increased AUC and 29% increased AUC with
ketoconazole in rats respectively. The results are shown in
Table 4.
Walker et al. (2006) has done an inter-species comparison
of liver and small intestinal microsomal metabolisms of
Fluoranthene.
For all these studies related to CYPs; reliable methods for
determining enzyme activities are needed to characterize an
individual CYP enzyme and to obtain a tool for evaluation
of its role in drug metabolism in humans. Determining the
role of CYP enzymes in the metabolism of a compound
and evaluating the effect of NCEs on human CYP activities
are key issues in pharmaceutical development as they may ex-
plain inter-subject variability, drug–drug interactions, non-
linear pharmacokinetics and toxic effects. Different liquid
chromatography tandem mass spectrometry methodologies
have been developed recently by Lahoz et al. (2008) for the
fast and routine analysis of major in vivo and in vitro CYPs
enzyme activities. They have also reviewed most recent ap-
proaches to quickly assess CYPs activities using in vitro mod-
els as well as their application in early drug discovery (Lahoz
et al., 2008).
5. P-gp
The MDR1 gene product, P-glycoprotein, a multidrug efﬂux
pump, an ATP-binding cassette transmembrane transporter
(ABC transporter), ﬁrst recognized in tumor resistance
(Leveque and Jehl, 1995); is expressed on the brush border
membrane of enterocytes to excrete its substrates into the lu-
men (Ambudkar et al., 1999; Janice and Barry, 1997).
Hence, in addition to CYP3A/3A4, we have to consider
the role of P-gp in reducing oral bioavailability. Greiner
et al. (1999) demonstrated this fact by examining the inter-
action between digoxin and rifampin in humans. Since, in
humans, digoxin is a good substrate for P-gp, but not for
CYP3A4, the role of P-gp can be directly demonstrated by
this experiment. They determined AUC of digoxin before
and after oral and intravenous administration before and
after co administration with rifampin (Greiner et al.,
1999). They have obtained a signiﬁcant correlation between
the AUC’s of digoxin after oral administration and P-gp
expression levels in the intestine. Analytical reports alsoTable 4 Increased AUC of albendazole sulfoxide when co
administered with verapamil, Ivermecitin, quinidine, ketocon-
azole in rats and sheep.
Animal Increased AUC when co administered with
Verapamil Ketoconazole Quinidine Ivermectin
Rats 43% 29% – –
Sheep 53.68% – 78.62% 50.55%
Figure 6 Mechanism of action of P-gp.
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the Tmax of digoxin; since rifampin is an inducer of P-gp.
The role of liver in determining the oral bioavailability is
negligible, since the hepatic extraction of digoxin after intra-
venous administration is minimal. Collectively these results
suggest that intestinal P-gp is involved in the reduced bio-
availability of digoxin following rifampin treatment. Re-
cently, the role of P-gp in determining the oral
bioavailability of digoxin in humans was also highlighted
in relation to a single nucleotide polymorphism of the
MDR1 gene. Hoff et al. (2000) demonstrated that a poly-
morph in exon 26 (C3435T) results in a reduced intestinal
expression level of P-gp along with an increased bioavailabil-
ity of digoxin.
The role of P-gp in reducing oral bioavailability of its sub-
strates has also been suggested by comparing the disposition in
normal and MDRl knock out mice. For digoxin, the intestinal
excretion after IV administration was signiﬁcantly lower in
MDR (/) mice compared to normal mice (Mayer et al.,
1996; Schinkel et al., 1997). Moreover, this intestinal excretion
was abolished by oral PSC833, a potent P-gp inhibitor (Mayer
et al., 1997). Same study was performed with paclitaxel (Spar-
renboom et al., 1997) and HIV protease inhibitors (Kim et al.,
1998) (indinavir, nelﬁnavir and saquinavir). The role of P-gp in
the excretion of its substrates into the human intestinal lumen
from the blood circulation has also been highlighted by the
ﬁndings of Gramette and Oertel (1999). They demonstrated
that talinolol, b-adrenergic receptor antagonist was excreted
into the intestinal lumen of healthy volunteer and which was
inhibited by R-verapamil.
Quinidine, P-gp substrate/inhibitor was found to interfere
with etoposide (an anticancer agent) absorption as well as
metabolism (Kolars et al., 1994). Hunter et al. (1997) have
used verapamil and monoclonal antibody MRK6 as P-gp
inhibitors increasing the absorptive ﬂux when studied in
Caco-2 cells. Some surfactants like Tween 80 and Cremophore
EL, which exhibit their effects by inhibition of P-gp, were
found to contribute in minimizing the oral bioavailability of
peptides across the intestine (Augustins et al., 1993; Neurkar
et al., 1996; Woodcock et al., 1992).
Moving further Jason et al., 2004 have studied the relation-
ship between copolymer concentration and substrate hydro-
phobicity on P-glycoprotein efﬂux inhibition by amphiphilic
diblock copolymers. Comparisons between the micelle associ-
ation and Caco-2 cellular accumulation were evaluated using
two structurally homologous P-gp substrates, the relatively
hydrophobic R-6G and the hydrophilic R-123, over concentra-
tions above and below the CMC for MePEG-b-PCL diblock
copolymers. An approximately 3.75-fold enhancement of R-
123 accumulation occurred with 2 mM MePEG17-b-PCL5,
compared to approximately 1.25-fold for R-6G. The effective
concentration range for surfactant mediated inhibition of P-
gp appears to depend on P-gp substrate hydrophobicity (Jason
et al., 2004; Norris et al., 1998).
Micuda et al. (2008) studied the effects of disease states on
the metabolism of P-gp substrates. They explained the im-
paired elimination of P-gp substrates after short-term cholesta-
sis that may commonly occur in clinical practice; by studying
in vivo biliary and renal excretion of rhodamine 123
(Rho123), a P-glycoprotein (P-gp) substrate, in rats during
either acute or chronic cholestasis induced by bile duct
obstruction (BDO) (Micuda et al., 2008).6. CYP3A & P-gp bisubstrates
Since the substrate speciﬁcity of CYP3A and P-gp overlap
each other, these two proteins act synergistically in reducing
the bioavailability of their substrates after oral administration.
Xenobiotics are taken up by enterocytes and metabolized there
by CYP enzymes. Drug molecules, which escape metabolic
conversion, are eliminated from the cells into the lumen via
P-gp. The drug molecules in the lumen may repeat the same cy-
cle, resulting in repeated exposure to metabolic enzymes, fur-
ther reducing intestinal bioavailability (Watkins, 1997;
Wacher et al., 1998; Benet et al., 1999) (see Fig. 6).
It is difﬁcult to evaluate the relative role played by these
two kinds of proteins in determining the oral bioavailability.
Benet et al., 2004 discovered one of the ﬁrst drug efﬂux–metab-
olism alliances in (Benet et al., 2004). They have used Caco-2
colon carcinoma cell line treated with sodium butyrate, phobal
ester, and 12–0 teradecanoylphorbol-13-acetate (Cummins
et al., 2003) (TPA) as a model for human intestinal drug
absorption. They have examined the transport and metabolism
of two P-gp and CYP3A4 co substrates (K77 and sirolimus)
and two CYP3A4 substrates (midazolam and felodipine). They
were dosed on the apical side of cells (mimicking human intes-
tinal absorption) alone or in combination with the P-gp inhib-
itor GG918 or dual P-gp and CYP3A inhibitor cyclosporine.
The results are shown in Table 5.
These data support the role of P-gp in increasing the expo-
sure of drugs to CYP3A4 in the intestine by allowing repeated
cycling of drug via diffusion and active efﬂux. Cummins et al94
used CYP3A expressing Caco-2 cell model while CYP3A4
transfected Caco-2 cells were used along with sirolimus and
midazolam by Cummins et al. (2004) and Lampen et al. (1998).
But Beverly et al. (2006) have theoretically stated that,
in vitro approaches published to date, involving determination
of ER, cannot dissect how P-gp affects CYP3A metabolism
from the overall outcome in terms of intestinal epithelium or
cell monolayer mediated extraction. Furthermore he suggested
the use of pharmacokinetic theory, for understanding the rele-
vance of P-gp/CYP3A interplay.
Zhang et al. (2007) evaluated whether curcumin could mod-
ulate P-glycoprotein (P-gp) and CYP3A expression, and in
turn modify the pharmacokinetic proﬁles of P-gp and CYP3A
substrates in male Sprague–Dawley rats. Regular curcumin
consumption had caused the C(max) and area under the con-
centration–time curve (AUC(0–8) and total AUC) of peroral
Table 5 Extraction ratio of cyclosporine when coadministered with K77, sirolimus, midazolam and felodipine.
Drug Substrate for Eﬄux ratio B-A/A-B Extraction Ratio present
3A4 P-gp Drug alone Drug cyclosporine Drug ± GG918
K77 Yes Yes 9 33 (3) 5.7 (0.1) 14 (1)
Sirolimus Yes Yes 2.5 60 (5) 15 (1) 45 (1)
Midazolam Yes No 1 25 (2) 10 (1) 23 (2)
Felodipine Yes No 1 26 (1) 14 (1) 24 (2)
Loss of orally administered drugs in GI tract 339celiprolol (a P-gp substrate with negligible cytochrome P450
metabolism) at 30 mg/kg to increase, but the apparent oral
clearance (CL(oral)) of the drug was reduced. Similarly, rats
treated with curcumin for 4 consecutive days showed a higher
AUC (AUC(0–4) and total AUC) and lower CL(oral) for per-
oral midazolam (a CYP3A substrate that does not interact
with the P-gp) at 20 mg/kg in comparison with vehicle-treated
rats (Zhang et al., 2007).
Lina and Eileen (2001) have examined the role of CYP450
1A1 and 1A2 in the metabolism of BG and identiﬁed the pos-
sible drug–drug interactions with DTIC. They have found that
BG is a potent inhibitor of CYP1A1 and CYP1A2. BG and 8-
oxoBG inhibit the conversion of DTIC to its active methylat-
ing agent. BG inhibition of DTIC conversion to an active
methylating species suggests that the combination in human
clinical trials should be approached with caution (Lina and Ei-
leen, 2001).
Hirunpanich et al. (2008) evaluated the effects of docosa-
hexaenoic acid (DHA) on the intestinal cytochrome P450 iso-
enzyme (CYP3A) and P-glycoprotein (P-gp) functions using
midazolam and rhodamine-123 as speciﬁc substrates of
CYP3A and P-gp, respectively. The intestinal extraction ratio
(ER G) of midazolam was determined to be 0.43 and decreased
signiﬁcantly to 0.12, 0.07, and 0.06 in the presence of 50, 100,
and 200 lM of DHA, respectively, in a concentration-depen-
dent manner. The results from an in vitro study using rat intes-
tinal microsomes demonstrated that DHA competitively
inhibited the intestinal CYP3A activity with Ki of 15.7 and
27.1 lM for the formation of 10-OH midazolam and 4-OH
midazolam, respectively (Hirunpanich et al., 2008).
Ogasawara et al. (2007) evaluated the intestinal ﬁrst-pass ef-
fect of midazolam (MDZ) and fexofenadine (FEX), typical
substrates for CYP3A and P-glycoprotein (P-gp), respectively,
with ketoconazole (KTZ) as a potent dual CYP3A/P-gp inhib-Table 6 Substrates common between cytochrome3A and P-
gp.
P-gp () P-gp substrate P-gp substrate and ()
Amiodarone Dexamethasone Cortisol
Erythromycin Etoposide Cyclosporine
Felodipine Rapamycin Diltiazem
Itraconazole Taxol Nicardipine
Ketoconazole Vinca alkaloids Verapamil
Lidocaine
Nifedipine
Nitrendipine
Progesterone
Quinidine
Tamoxifenitor in cynomolgus monkeys. When MDZ or FEX was admin-
istered i.v. at doses of 0.3 or 1 mg/kg, respectively, the plasma
concentration–time proﬁles were not inﬂuenced by p.o. coad-
ministration of KTZ (20 mg/kg). On the other hand, when
MDZ or FEX was administered p.o. at doses of 1 or 5 mg/
kg, respectively, concomitant with p.o. KTZ (20 mg/kg), sig-
niﬁcant increases were observed in the area under the plasma
concentration–time curves of MDZ or FEX (22-fold in
MDZ and 3-fold in FEX). These ﬁndings indicate that both
CYP3A and P-gp play a key role in the intestinal barrier and
that the inhibition of intestinal CYP3A/P-gp activities contrib-
utes exclusively toward the drug–drug interactions (DDI) with
KTZ. These results also suggest that monkeys may be an
appropriate animal species for evaluating the intestinal ﬁrst-
pass effect of p.o. administered drugs and for predicting the
intestinal DDI related to CYP3A4 and P-gp in humans (Oga-
sawara et al., 2007).
Wacher et al. (1995) had given some of the overlapping sub-
strates between cytochromes 3A and P-gp as – CYP3A sub-
strates that also interact with P-gp. They are shown in Table 6.7. Phase II metabolism in intestine
7.1. Glucuronosyl transferase – (GT)
Studies of human intestinal Phase II metabolism have been di-
rected toward several drugs that undergo signiﬁcant 1st pass
metabolism as well as isozyme speciﬁc substrate probes (Benet
and Cummins, 2001). Gut activity is reported for estradiol and
17b-estradiol (Diczfaluzy et al., 1962), ethinyl estradiol (Back
et al., 1981), acetaminophen (Ueda et al., 1992), p-nitrophenol,
bilirubin (Peters et al., 1991), morphine (Paciﬁci et al., 1986;
Cappiello et al., 1991) and propofol (Raoof et al., 1996).
In comparison with the liver, scientists are not having un-
ique opinion. For example, maximal conjugation rates for
morphine and ethinyl estradiol were approx. 1/10th to 1/5th
for ileal tissue in comparison with the liver, when data were ex-
pressed in terms of per gram tissue wt (Cappiello et al., 1991).
In contrast the maximal rate of morphine glucoronidation (per
gram protein) in the liver and intestinal mucosal homogenates
differed by only two fold (Paciﬁci et al., 1986). In another
study, microsomes isolated primarily from human jejunal
and duodenal mucosa catalyzed propofol conjugation at a
maximal rate that was 89% of the corresponding liver micro-
somal rate.
Trevor et al. have used cultures of the human colorectal
carcinoma line, HT29, to assess the susceptibility to glucuron-
idation of the cytostatic, immunosuppressive drug mycophen-
olic acid (MPA) and 19 of its analogs. They suggested that
cultures of human colorectal carcinoma cell lines may provide
Figure 7 Relationship between absolute bioavailability (F) and
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novel synthetic compounds to both Phase I and Phase II met-
abolic conversions (Franklin et al., 1997).
7.2. Sulfotransferase
Cytosolic sulfotransferase activity is distributed in several or-
gans of the body, including those of the gastrointestinal tract.
Multiple isozymes have been identiﬁed and four types are de-
tected as estrogen sulfotransferase, dehydropiandrosterone
sulfotransferase, M form of phenol sulfotransferase (Paciﬁci
et al., 1993a, Pesola and Walle, 1993), as well as thermolabile
monoamine metabolizing surfotransferase (Paciﬁci et al.,
1993b). Human intestinal mucosa catalyzes the sulfation of
ethinyl estradiol (Back et al., 1981; Paciﬁci et al., 1993a), iso-
proterenol (Paciﬁci et al., 1993a), and terbutaline (Paciﬁci
et al., 1993b). In case of terbutaline cytosol of small intestinal
mucosa exhibits a greater Vmax activity than liver cytosol
(Paciﬁci et al., 1993b) suggesting a key role for the gut wall
in the pronounced ﬁrst-pass elimination of orally administered
drugs. But a dose ranging study with intact mucosa (using
chamber) and acetaminophen as a substrate suggests that
intestinal sulfotransferase activity is readily saturated (Paciﬁci
et al., 1993b).
Meinl et al. (2008) found differentiation-dependent expres-
sion of SULT in the Caco-2 and TC7 cultured cells reﬂecting
the in vivo situation, where SULT expression is focused on dif-
ferentiated enterocytes. This is concluded from the study of
benzo[a]pyrene metabolism.
7.3. N-Acetyl transferase
N-Acetyl transferase indicates an extensive presystemic acety-
lation activity in both the liver and intestine (Ilett et al.,
1990) for the metabolites of prodrug sulfasalazine (s-aminosal-
icylic acid and sulfapyridine).
In contrast to regional differences in P450 expression, N-
acetyl transferase activities appear to be of similar magnitude
throughout the entire small intestine (Hickman et al., 1995).
7.4. S-Methyl transferase
S-Methyl transferase exhibits the same level of metabolic activ-
ity as that of the liver (Paciﬁci et al., 1991, 1993b). It was found
to be responsible for extensive metabolism of 6-
mercaptopurine.
7.5. Thiopurine methyl transferase
Thiopurine methyl transferase shows similar metabolic pattern
as that of s-methyl transferase. Its most recognized substrate is
captopril (Hickman et al., 1995; Paciﬁci et al., 1991).
7.6. Glutathione s-transferase
Three forms of Glutathione s-transferase a, l and p have been
identiﬁed in human small and large intestines (Dewaziers et al.,
1990; Mckay et al., 1993; Her et al., 1996; Prueksaritanont
et al., 1996). But a signiﬁcant role of this enzyme in reducing
oral bioavailability of drugs remains undeﬁned.7.7. Variability
Unfortunately, an enzymatic metabolic barrier that limits oral
bioavailability often brings with it the problem of signiﬁcant
inter-individual variability in systemic blood concentrations
of drug. It is the consequence of variability in metabolic en-
zyme expression (Burton et al., 1993). Understanding the bio-
chemical and physiological basis for variability in the extent of
loss of orally administered drug is an essential step in optimiz-
ing oral drug therapy.
To cite the importance of variability in absolute bioavail-
ability, the graphical interpretation indicating relationship be-
tween absolute bioavailability (F) and inter-subject variability
(CV) is shown in Fig. 7).
Also because of unique anatomical location, enzymes of the
gut wall represent an important and highly sensitive site for
metabolically based interactions of orally administrated drugs.
Again inter individual variability may make it impossible to
predict the likelihood of an interaction in any given patient.
Hopefully, newer models for studying human gut wall meta-
bolic extraction will provide the means to predict the average
extraction ratio and maximum ﬁrst pass availability of sub-
strates.123 With these models it has been possible to examine
the sources of inter individual variability in drug bioavailability
including variable constitutive enzyme expression (both genetic
and environmentally determined), enzyme induction by drugs,
disease and diet and intrinsic/acquired differences in plasma
protein binding and organ blood ﬂow (food and drug effects).
7.7.1. Problems in modeling intestinal extraction
As enlisted by Thummel et al. (1996) some problems in mod-
eling intestinal extraction are enlisted below.
(1) There is no uniform perfusion of the intestine by drug
after oral administration. Also diffusional movement
of drug across the apical epithelial cell and into the
splanchnic capillaries competes with intracellular meta-
bolic clearance.inter-subject variability (CV).
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the same time since drug distribution is not uniform
across the entire intestine.
(3) The intestinal transit time creates a source of intra and
inter individual variability.
(4) Presence and distribution of P-gp and other efﬂux trans-
porters interfere with intestinal extraction.
7.7.2. Well-stirred model of extraction (Thummel et al., 1996)
This model relates the biochemical variable i.e. unbound
intrinsic clearance to the organ extraction ratio. It is based
on the assumption that:
(a) There is a homogeneous distribution of enzymes for all
regions.
(b) Blood ﬂow to mucosa is a fraction of total arterial blood
ﬂow to the small intestine.
(c) Drug distributes rapidly between the mucosal apical epi-
thelium and the splanchnic capillaries.
The model states that,
EI ¼ Clin: u
Clin: uþQSMA  fv
where EI, intestinal extraction ratio; Clin. u, unbound intrinsic
clearance; QSMA, total blood ﬂow to the superior mesenteric
artery present in mucosa and fv, fraction of total arterial ﬂow.
Chen and Pang (1997) successfully used the well stirred
intestinal model to demonstrate the inﬂuence of saturability
of intestinal metabolism for highly extracted 4-methyl umbel-
iferone on sequential biotransformation within the liver and
intestine. They have used a vascularly perfused system for drug
delivery to the enzyme rather than luminal administration.
7.7.3. Drawback
Predicting the effect of any splanchnic blood ﬂow modulator
on gut wall metabolism is difﬁcult by this formula (like stren-
uous physical activity, ingestion of food, vascular acting co
medication, posture, exercise etc.).
Galetin (2007) has shown comparable intestinal and hepatic
catalytic activities (when expressed per pmol of P450 enzyme)
of the major P450 enzymes. Hence he concluded that once nor-
malized for the relative abundance of the enzyme investigated,
hepatic or recombinant data would be equally useful for the
prediction of intestinal clearance once an appropriate mecha-
nistic model is applied (Galetin, 2007).
8. Conclusion
Thus over recent years a number of studies have assessed the
catalytic activity of intestinal metabolic enzymes in comparison
with the liver, focusing predominantly on CYP3A4/CYP3A5 as
well as a range of glucuronidating (UGT) enzymes. Although
intuitively one would expect the activity of enzymes in both or-
gans to be comparable, a number of in vitro as well as in vivo
studies have reported differential importance of the intestine
relative to the liver. In addition, inter-individual variability in
P450/UGT expressions in both the liver and intestine and their
relative abundance in the corresponding organs have generally
not been taken into account. Although this approach is appli-cable to P450 enzymes, certain speciﬁc issues need to be ad-
dressed in case of Phase II enzymes. For example, the relative
UGT expression levels in vivo are not clearly deﬁned.
9. Future trends
Examining the effects of uptake transporters, efﬂux transport-
ers and metabolizing enzymes on metabolic processes is an
exciting area for future research because, a number of other
transporter metabolism pairs exhibit similar phenomena as
that of MDRl–CYP3A4. MPR2 and UGTs are one of them.
Concerning the synergistic role of conjugation enzymes/car-
boxyesterases and efﬂux transporters, little information is
available for the human small intestine, although some reports
have been published on the disposition in experimental ani-
mals and Caco-2 cells. For more precise analysis, transporter
molecules responsible for the cellular extrusion of these conju-
gated metabolites need to be cloned and studied. A recent
study by Cao et al. indicated a 3-fold higher expression of
UGTs relative to CYP3A4 in human duodenum. However,
as the expression of intestinal metabolic enzymes, and trans-
porters, follows certain gradient patterns along the intestine
and within the villi, this will not necessarily reﬂect the
UGT:P450 abundance ratio along the whole length of the
gut. In addition, the identiﬁcation of appropriate extrahepatic
scaling factors represents a major challenge. Only recently, has
a consensus on such numbers been reached for the scaling of
hepatic data, and there is no such comprehensive data avail-
able for the analysis of the intestinal microsomal recovery.
Also the factors like drug concentrations, site-dependence of
metabolic enzyme expression, induction or inhibition of en-
zyme site expression and interactions with physiologic luminal
contents or co-administered drugs or exipients require more re-
search in order to develop a full understanding of the absorp-
tion and poor bioavailability of drugs.
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